Alexion Pharmaceuticals — Cyborg Score 8/10

Strategic Profile

Alexion has pioneered complement inhibition for a broad spectrum of immune-mediated rare diseases caused by uncontrolled activation of the complement system, with its franchise including Soliris (eculizumab), a first-in-class anti-complement component 5 (C5) monoclonal antibody. Research focuses on innovative molecules and targets in the complement cascade, while development work focuses on haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology.

Cyborg Score Rationale

Alexion maintains a leading rare disease franchise with innovative pipeline and strong commercial products. As part of AstraZeneca, it benefits from enhanced resources and global infrastructure while retaining specialized rare disease focus.

Top Insights

• Complement inhibition leadership with dual blockbusters ULTOMIRIS and SOLIRIS across rare immune-mediated diseases
• Diversified portfolio spanning hematology, nephrology, neurology, metabolic disorders, cardiology and ophthalmology
• AstraZeneca acquisition (2021) provides scale while maintaining rare disease specialization
• Key growth drivers in neurology expansion (gMG, NMOSD) and ANDEXXA coagulation franchise

Named Competitors

• Soliris — C5 complement inhibitor for rare immune-mediated diseases
• Pegcetacoplan — Complement inhibitor for rare diseases
• Iptacopan — Factor B inhibitor for rare disease indications

Open the full interactive Alexion Pharmaceuticals report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.